Piramal Pharma Past Earnings Performance
Past criteria checks 1/6
Piramal Pharma's earnings have been declining at an average annual rate of -130.3%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 10.2% per year. Piramal Pharma's return on equity is 0.2%, and it has net margins of 0.2%.
Key information
-130.3%
Earnings growth rate
-157.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.2% |
| Return on equity | 0.2% |
| Net Margin | 0.2% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Piramal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 83,466 | 178 | 20,295 | 0 |
| 31 Dec 23 | 78,435 | -333 | 22,171 | 0 |
| 30 Sep 23 | 76,009 | -1,336 | 21,856 | 0 |
| 30 Jun 23 | 74,096 | -1,760 | 21,396 | 0 |
| 31 Mar 23 | 71,427 | -1,865 | 21,046 | 0 |
| 31 Dec 22 | 72,228 | -325 | 20,064 | 0 |
| 30 Sep 22 | 69,535 | 2,210 | 1,409 | 0 |
| 30 Jun 22 | 67,532 | 2,626 | 16,545 | 0 |
| 31 Mar 22 | 67,341 | 3,760 | 15,888 | 0 |
| 31 Mar 21 | 58,868 | 7,708 | 14,762 | 0 |
Quality Earnings: 543635 has a large one-off loss of ₹627.9M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 543635 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 543635's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 543635 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 543635 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.4%).
Return on Equity
High ROE: 543635's Return on Equity (0.2%) is considered low.